JP2008524261A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008524261A5 JP2008524261A5 JP2007547054A JP2007547054A JP2008524261A5 JP 2008524261 A5 JP2008524261 A5 JP 2008524261A5 JP 2007547054 A JP2007547054 A JP 2007547054A JP 2007547054 A JP2007547054 A JP 2007547054A JP 2008524261 A5 JP2008524261 A5 JP 2008524261A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- seq
- influenza
- composition
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 claims description 43
- 102000037865 fusion proteins Human genes 0.000 claims description 43
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 claims description 32
- 102000018697 Membrane Proteins Human genes 0.000 claims description 28
- 108010052285 Membrane Proteins Proteins 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 27
- UPAQRWMRKQCLSD-HTIIIDOHSA-N 2,3-dipalmitoyl-S-glycerylcysteine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CSC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC UPAQRWMRKQCLSD-HTIIIDOHSA-N 0.000 claims description 22
- 108010038122 S-(2,3-bis(palmitoyloxy)propyl)cysteine Proteins 0.000 claims description 22
- 101100115709 Mus musculus Stfa2 gene Proteins 0.000 claims description 20
- 101100311241 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) STF2 gene Proteins 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108010040721 Flagellin Proteins 0.000 claims description 14
- 108010084333 N-palmitoyl-S-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-lysine Proteins 0.000 claims description 13
- 241000607142 Salmonella Species 0.000 claims description 11
- 101150104647 fljB gene Proteins 0.000 claims description 11
- 108700010900 influenza virus proteins Proteins 0.000 claims description 11
- 241000588724 Escherichia coli Species 0.000 claims description 8
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims description 7
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims description 7
- 101710154606 Hemagglutinin Proteins 0.000 claims description 6
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 6
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 6
- 101710176177 Protein A56 Proteins 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims description 3
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims description 3
- 241000712431 Influenza A virus Species 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims 17
- 244000052769 pathogen Species 0.000 claims 17
- 230000001717 pathogenic effect Effects 0.000 claims 17
- 239000000556 agonist Substances 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 230000028993 immune response Effects 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 230000004936 stimulating effect Effects 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 241000713196 Influenza B virus Species 0.000 claims 3
- 241000713297 Influenza C virus Species 0.000 claims 3
- 102000005348 Neuraminidase Human genes 0.000 claims 2
- 108010006232 Neuraminidase Proteins 0.000 claims 2
- 239000000185 hemagglutinin Substances 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 description 49
- 108091028043 Nucleic acid sequence Proteins 0.000 description 40
- 150000001413 amino acids Chemical class 0.000 description 28
- 230000028327 secretion Effects 0.000 description 18
- 101150038062 fliC gene Proteins 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 7
- 102400001018 Proadrenomedullin N-20 terminal peptide Human genes 0.000 description 7
- PIRWNASAJNPKHT-SHZATDIYSA-N pamp Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)N)C(C)C)C1=CC=CC=C1 PIRWNASAJNPKHT-SHZATDIYSA-N 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 208000037797 influenza A Diseases 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 3
- 102000002689 Toll-like receptor Human genes 0.000 description 3
- 108020000411 Toll-like receptor Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
- 102100036826 Aldehyde oxidase Human genes 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 2
- 102000003792 Metallothionein Human genes 0.000 description 2
- 108090000157 Metallothionein Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 102000028557 immunoglobulin binding proteins Human genes 0.000 description 2
- 108091009323 immunoglobulin binding proteins Proteins 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 108700022810 Drosophila Hsc70-3 Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100120241 Salmonella muenchen fliC gene Proteins 0.000 description 1
- 101900195698 Salmonella typhimurium Flagellin Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- -1 by synthesis (eg Proteins 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63825404P | 2004-12-21 | 2004-12-21 | |
| US63835004P | 2004-12-21 | 2004-12-21 | |
| US64506705P | 2005-01-19 | 2005-01-19 | |
| US65320705P | 2005-02-15 | 2005-02-15 | |
| US66687805P | 2005-03-31 | 2005-03-31 | |
| US68207705P | 2005-05-18 | 2005-05-18 | |
| US74120205P | 2005-11-30 | 2005-11-30 | |
| PCT/US2005/046662 WO2006069262A2 (en) | 2004-12-21 | 2005-12-21 | Compositions of influenza viral proteins and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008524261A JP2008524261A (ja) | 2008-07-10 |
| JP2008524261A5 true JP2008524261A5 (enExample) | 2009-02-12 |
Family
ID=36272492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007547054A Pending JP2008524261A (ja) | 2004-12-21 | 2005-12-21 | インフルエンザウイルスタンパク質の組成物およびその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1831259A2 (enExample) |
| JP (1) | JP2008524261A (enExample) |
| AU (2) | AU2005319141B8 (enExample) |
| BR (1) | BRPI0519705A2 (enExample) |
| CA (1) | CA2593746A1 (enExample) |
| MX (1) | MX2007007586A (enExample) |
| NZ (1) | NZ556004A (enExample) |
| SG (1) | SG160424A1 (enExample) |
| WO (1) | WO2006069262A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008527009A (ja) | 2005-01-19 | 2008-07-24 | バクシネート コーポレーション | 病原体関連分子パターンおよび抗原を含む組成物ならびに免疫応答を刺激するためのそれらの使用 |
| EP2476432B1 (en) | 2006-03-07 | 2015-08-19 | Vaxinnate Corporation | Compositions that include hemagglutinin, methods of making and methods of use thereof |
| EP2012829A4 (en) * | 2006-04-24 | 2010-04-21 | Protelix Inc | PROCESS FOR PRODUCING VIRAL VACCINE AND THERAPEUTIC PEPTIDE ANTIGENS |
| ES2520026T3 (es) * | 2006-09-18 | 2014-11-11 | The Board Of Trustees Of The University Of Arkansas | Composiciones y métodos para potenciar respuestas inmunitarias |
| EP1925318A1 (en) * | 2006-11-20 | 2008-05-28 | Paul-Ehrlich-Institut | Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu |
| US8778847B2 (en) * | 2007-06-13 | 2014-07-15 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Immunogenic peptides of influenza virus |
| ES2539818T3 (es) | 2007-08-02 | 2015-07-06 | Biondvax Pharmaceuticals Ltd. | Vacunas contra la gripe multiepitópicas multiméricas |
| GB0720250D0 (en) | 2007-10-17 | 2007-11-28 | Univ Edinburgh | Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof |
| US8470771B2 (en) | 2007-11-14 | 2013-06-25 | Institute Of Microbiology, Chinese Academy Of Sciences | Method and medicament for inhibiting the infection of influenza virus |
| SG190562A1 (en) | 2008-04-18 | 2013-06-28 | Vaxinnate Corp | Deletion mutants of flagellin and methods of use |
| JP2012523379A (ja) | 2009-04-09 | 2012-10-04 | ザ ユニバーシティー オブ メルボルン | 免疫原性組成物およびその使用 |
| MX348663B (es) * | 2009-09-08 | 2017-05-26 | Inst Tecnologico Estudios Superiores Monterrey | Proceso de producción de una vacuna recombinante, dicha vacuna expresable en cepas de escherichia coli y su uso para combatir la influenza a h1ni1 brote 2009. |
| MX2012007916A (es) * | 2010-01-06 | 2012-11-06 | Vaxinnate Corp | Metodos y composiciones para proporcionar inmunidad protectora en los adultos mayores. |
| CN102811734B (zh) | 2010-01-21 | 2016-02-10 | 阿肯色大学评议会 | 增强免疫应答的疫苗载体和方法 |
| AU2011230491A1 (en) * | 2010-03-26 | 2012-10-18 | Emergent Product Development Gaithersburg Inc. | Ectodomains of influenza Matrix 2 protein, expression system, and uses thereof |
| GB201009273D0 (en) * | 2010-06-03 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel vaccine |
| JP2013537892A (ja) * | 2010-09-22 | 2013-10-07 | ザ ユニバーシティー オブ メルボルン | 新規な免疫賦活法 |
| WO2012114323A1 (en) | 2011-02-22 | 2012-08-30 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |
| US8932598B2 (en) | 2012-08-28 | 2015-01-13 | Vaxinnate Corporation | Fusion proteins and methods of use |
| US9889189B2 (en) | 2012-11-05 | 2018-02-13 | Georgia State University Research Foundation | Universal influenza vaccine based on heterologous multiple M2E proteins |
| RU2571944C1 (ru) * | 2014-10-17 | 2015-12-27 | Общество с ограниченной ответственностью "НТфарма" | Противогриппозная вакцина широкого спектра действия против птичьего гриппа а на основе эктодомена белка м2 |
| BR112020012360A2 (pt) | 2017-12-21 | 2020-11-24 | Ena Therapeutics Pty Ltd | compostos otimizados |
| WO2020257870A1 (en) | 2019-06-26 | 2020-12-30 | Ena Therapeutics Pty Ltd | Novel molecules |
| WO2023028661A1 (en) * | 2021-09-02 | 2023-03-09 | Ena Respiratory Pty Ltd | Formulation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7569225B2 (en) * | 2002-08-12 | 2009-08-04 | The Council Of The Queensland Institute Of Medical Research | Immunogenic lipopeptides comprising T-helper and B-cell epitopes |
| MXPA05009580A (es) * | 2003-03-07 | 2005-10-19 | Merck & Co Inc | Vacuna contra el virus de la influenza. |
-
2005
- 2005-12-21 JP JP2007547054A patent/JP2008524261A/ja active Pending
- 2005-12-21 EP EP05855253A patent/EP1831259A2/en not_active Withdrawn
- 2005-12-21 MX MX2007007586A patent/MX2007007586A/es not_active Application Discontinuation
- 2005-12-21 BR BRPI0519705-8A patent/BRPI0519705A2/pt not_active IP Right Cessation
- 2005-12-21 CA CA002593746A patent/CA2593746A1/en not_active Abandoned
- 2005-12-21 WO PCT/US2005/046662 patent/WO2006069262A2/en not_active Ceased
- 2005-12-21 SG SG201001924-8A patent/SG160424A1/en unknown
- 2005-12-21 NZ NZ556004A patent/NZ556004A/en not_active IP Right Cessation
- 2005-12-21 AU AU2005319141A patent/AU2005319141B8/en not_active Ceased
-
2010
- 2010-01-07 AU AU2010200048A patent/AU2010200048A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008524261A5 (enExample) | ||
| KR101983989B1 (ko) | 인플루엔자 바이러스 백신 및 이의 용도 | |
| JP7094103B2 (ja) | インフルエンザウイルスワクチンおよびその使用 | |
| JP6285469B2 (ja) | 呼吸器合胞体ウイルスの熱安定な融合前ｆタンパク質オリゴマーおよび免疫組成物におけるその使用 | |
| CN106661091B (zh) | 流行性感冒病毒疫苗及其用途 | |
| CA2913859A1 (en) | Influenza virus vaccines and uses thereof | |
| CN109678937B (zh) | H3n2亚型流感病毒血凝素蛋白的突变体及其应用 | |
| KR102379951B1 (ko) | 인플루엔자 핵단백질 백신 | |
| US9896484B2 (en) | Influenza virus recombinant proteins | |
| TW202317600A (zh) | 預防多種病毒感染的多價疫苗 | |
| WO2023064631A1 (en) | Engineering antigen binding to, and orientation on, adjuvants for enhanced humoral responses and immunofocusing | |
| Yu et al. | Fine mapping and conservation analysis of linear B-cell epitopes of peste des petits ruminants virus hemagglutinin protein | |
| Wang et al. | Immunogenicity of a bovine viral diarrhea virus E2–C3d fusion protein containing a bovine homolog of C3d | |
| JP2018052953A (ja) | インフルエンザウイルスワクチンおよびその使用 | |
| CN118176204A (zh) | 截短的流感神经氨酸酶及其使用方法 | |
| Choi et al. | Immune response induced by the TAT-conjugated influenza M2e in mice | |
| Van et al. | Bio-functional enhancement of plant based-haemagglutinin by fusion with IgMFc | |
| CN115197303A (zh) | 一种s蛋白的受体结合结构域的突变体及其应用 | |
| US20220267382A1 (en) | Chimeric hemagglutinin protein and a vaccine composition comprising the same | |
| HK1236966A1 (en) | Influenza virus vaccines and uses thereof | |
| HK1236966B (en) | Influenza virus vaccines and uses thereof | |
| TH112180A (th) | โปรตีนผสมชนิดใหม่ ๆ และการใช้โปรตีนเหล่านี้เพื่อการเตรียมวัคซีนต้านไวรัสตับอักเสบ ซี |